

ART UNIT:

1614

EXAMINER:

APPLICANT:

FIKSTAD, DAVID ET AL.

SERIAL NO.:

10/700,838

FILED:

11/3/2003

CONFRM. NO.: 5766

FOR:

"PHARMACEUTICAL

COMPOSITIONS WITH

SYNCHRONIZED SOLUBILIZER

RELEASE"

DOCKET NO.:

01235-23625

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8

DATE OF DEPOSIT: September 2/2006

I hereby certify that this paper or fee (along with any paper or fee referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as first class mail on the date indicated above and is addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA-22313-1450.

Jennifer Pogne

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir/Madam:

Please find, pursuant to 37 C.F.R. § 1.98(a)(1), the enclosed Form **PTO/SB/08A** which contains a list of all patents, publications, or other items that have come to the attention of one or more of the individuals designated in 37 C.F.R. § 1.56(c). Applicant respectfully submits that this Information Disclosure statement is filed pursuant to:


	37 C.F.R. §	1.97(b)(1) or (3)	, within three	months of	the filing	date of the
application,	or before a firs	t office action or	the merits, v	hichever o	occurs last	;

37 C.F.R. § 1.97(c), after a first office action on the merits, but before a Final Office Action or a Notice of Allowance, whichever occurs first, and is accompanied by either 1)

09/26/2006 GWORDOF1 00000028 10700838

01 FC:1806

180.00 OP



	Copies of the references listed in the accompan	nying Form PTO/SB/08A and
PTO/SB/08B	are NOT enclosed because, under 37 C.F.R. § 1	.98.(d), they were previously cited
by or submit	ted to the Office in application number	, which is relied upon for
an earlier fili	ng date under 37 C.F.R. § 1.20.	

For all listed references that are not either in the English language, or accompanied by a translation into English, a concise explanation of relevance as required under 37 C.F.R. § 1.98(a)(3) is enclosed attached to each.

The Commissioner is hereby authorized to charge any additional fees associated with this communication or to credit any overpayment to Deposit Account No. 20-0100.

Dated September 21, 2006.

Very truly yours,

David W. Osborne Attorney for Applicant Registration No. 44,989

THORPE NORTH & WESTERN, LLP Customer No. 20,551 P.O. Box 1219 Sandy, Utah 84091-1219 (801) 566-6633

DWO/PSS/jp Enclosures

PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Raderwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

tie for form 1449/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of

Complete if Known		
Application Number	10/700838	
Filing Date	11/03/2003	
First Named Inventor	DAVID FIKSTAD ET AL.	
Art Unit	1614	
Examiner Name		_
Attorney Docket Number	01235-23625	

			U. S. PATEN	DOCUMENTS	
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (ff known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		^{US-} 6589562	07-08-2003	Shefer et al.	
		^{US-} 5874418	02-23-1999	Stella et al.	
		^{US-} 6046177	04-04-2000	Stella et al.	
		^{US-} 6692766	02-17-2004	Rubinstein et al.	
		^{US-} 5989583	11-23-1999	Amselem	
		^{US-} 6887493	05-03-2005	Shefer et al.	
		US-			
*****		US-			
		US-			
•	 	US-			

	FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T⁵
		WO9850077	11-12-1998	Cydex Inc.		
						<u> </u>
						-
						-

	 _	
Examiner	 Date	
Signature	Considered	
	 	I

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.





IFW

David W. Osborne Registered Patent Attorney osborne@tnw.com

P. Scott Smith Registered Patent Attorney smith@tnw.com

September 20, 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Re:

U.S. Patent Application No. 10/700,838 filed 11/03/2003

Applicant: DAVID FIKSTAD ET AL.

Title: "PHARMACEUTICAL COMPOSITIONS WITH SYNCHRONIZED

SOLUBILIZER RELEASE"

Group Art Unit: 1614

Attorney Docket No.: 01235-23625

Sir/Madam:

Transmitted herewith for filing and pursuant to 37 C.F.R. §§ 1.56 and 1.97 is a Supplemental Information Disclosure Statement. Enclosed also are the following designated documents, as required under 37 C.F.R. §§ 1.97 and 1.98:

\boxtimes	Form PTO/SB/08A list of 7 references submitted for consideration.
	Legible copies of the listed references or their relevant portions.
\boxtimes	Legible copies of the listed <u>non-patent documents and foreign documents</u> or their relevant portions are included.
\boxtimes	Copies of U.S. patents and/or publications are not included pursuant to the Official Gazette Notice, dated Aug. 5, 2003, waiving the requirement of 37 C.F.R. 1.98(a)(2)(i).
	All English translations of each non-English reference, if any, within the possession, custody, control or availability of anyone designated in 37 C.F.R. § 1.56(c) (see 37 C.F.R. § 1.98(c)).

require		lowing are included within the Information Disclosure Statement if applicable and as 37 C.F.R. § 1.98:		
		Concise explanation of relevance of each reference not in English and unaccompanied by an English translation.		
		Statement that certain listed references not enclosed are substantially cumulative of an enclosed reference.		
		Statement that certain listed references not enclosed were previously cited by or submitted to the Office in prior application no. , filed on, which is relied upon for an earlier filing date under 35 U.S.C. § 120.		
In order to secure consideration of the items designated above, one or more of the following, if required, is also enclosed:				
		Statement under 37 C.F.R. § 1.97(e)(1) or (2).		
	\boxtimes	Check No. 26430 which includes the amount of \$180.00 (amount in § 1.17(p)) constituting the submission fee set forth in 37 C.F.R. § 1.17(p).		
	ent meet	event that 37 C.F.R. § 1.97(c) applies and the Examiner is not satisfied that the is the requirements of 37 C.F.R. § 1.97(e), or in any other event remediable by a fee, by over payment or charge any additional fees to Deposit Account No. 20-0100 of the		

Very truly yours,

David W. Osborne Attorney for Applicant Registration No. 44,989

THORPE NORTH & WESTERN, LLP Customer No. 20,551 P.O. Box 1219 Sandy, Utah 84091-1219 Telephone: (801) 566-6633

DWO/PSS/jp

undersigned.